NASDAQ:APVO

Aptevo Therapeutics Q3 2026 Earnings Results & Report

Aptevo Therapeutics logo
$0.40 -0.01 (-2.37%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$0.41 +0.00 (+1.21%)
As of 11/20/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Aptevo Therapeutics missed analyst earnings expectations in its Q3 2026 results, released November 16, 2026. The company reported EPS of -$5.19 versus the -$3.71 consensus estimate.

Earnings Announcement Details

Quarter
Q3 2026
Time
Before Market Opens

Aptevo Therapeutics EPS Results

Actual EPS
-$5.19
Consensus EPS
-$3.71
Beat/Miss
Missed by -$1.48
One Year Ago EPS
N/A
EPS Beat Rate
1 of last 4 quarters

Aptevo Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Aptevo Therapeutics Q3 2026 Earnings FAQ

Aptevo Therapeutics (NASDAQ:APVO) reported earnings of -$5.19 per share for Q3 2026, missing the consensus estimate of -$3.71. The report was announced on Monday, November 16, 2026.

Aptevo Therapeutics Earnings Headlines

Today's free pick (on me)
Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one lesser known company. With plans filed for 1,000,000 new satellites, that licensing fee could scale dramatically. Analyst Dylan says the stock could move by December 8th.tc pixel
Aptevo Reports 79% Remission Rate in TP53-Mutated AML
See More Aptevo Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Aptevo Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aptevo Therapeutics and other key companies, straight to your email.

About Aptevo Therapeutics

Aptevo Therapeutics (NASDAQ:APVO) is a biotechnology company focused on developing immunotherapies, particularly treatments for cancer. Its research uses engineered antibody-based approaches intended to direct or activate the immune system against disease.

The company’s programs have included APVO436, a bispecific antibody designed to connect CD3-positive T cells with CD123-positive leukemia cells and investigated as a potential treatment for acute myeloid leukemia. Aptevo has also worked on other immune-targeting candidates, including programs designed to stimulate immune responses against tumors.

Aptevo was established in 2016 as a spin-off from Emergent BioSolutions. The company is based in Seattle, Washington, and its work is centered on research and development rather than a broad portfolio of marketed medicines.

View Aptevo Therapeutics Profile